Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

294 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Management of Small Testicular Masses: A Delphi Consensus Study.
Pang KH, Fallara G, Lobo J, Alnajjar HM, Sangar V, von Stempel C, Huang DY, Parnham A, Cazzaniga W, Giganti F, Haider A, Sachdeva A, Albersen M, Alifrangis C, Bandini M, Castiglione F, De Vries HM, Fankhauser C, Heffernan Ho D, Nicol D, Shamash J, Thomas A, Walkden M, Freeman A, Muneer A; EAU-YAU Penile and Testis Cancer Working Group. Pang KH, et al. Among authors: albersen m. Eur Urol Oncol. 2024 Nov 4:S2588-9311(24)00239-6. doi: 10.1016/j.euo.2024.10.010. Online ahead of print. Eur Urol Oncol. 2024. PMID: 39500644
Reply to Jan Hrudka, Petr Waldauf, and Radoslav Matěj's Letter to the Editor re: Laura Elst, Gino Philips, Kaat Vandermaesen, et al. Single-cell Atlas of Penile Cancer Reveals TP53 Mutations as a Driver of an Aggressive Phenotype, Irrespective of Human Papillomavirus Status, and Provides Clues for Treatment Personalization. Eur Urol 2024;86:114-27.
Elst L, Albersen M. Elst L, et al. Among authors: albersen m. Eur Urol. 2024 Aug 19:S0302-2838(24)02554-5. doi: 10.1016/j.eururo.2024.08.018. Online ahead of print. Eur Urol. 2024. PMID: 39164170 No abstract available.
Baseline neutrophil-to-eosinophil-ratio and outcome in metastatic clear-cell renal cell carcinoma treated with nivolumab or ipilimumab/nivolumab.
Beulque Y, Kinget L, Roussel E, Mobaraki S, Laenen A, Debruyne PR, Van Herck Y, Baldewijns M, Wozniak A, Garg AD, Zucman-Rossi J, Couchy G, Albersen M, De Wever L, Haaker L, Beuselinck B. Beulque Y, et al. Among authors: albersen m. Acta Oncol. 2024 Aug 11;63:658-668. doi: 10.2340/1651-226X.2024.40390. Acta Oncol. 2024. PMID: 39129249 Free PMC article.
Author Correction: A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinoma.
Kinget L, Naulaerts S, Govaerts J, Vanmeerbeek I, Sprooten J, Laureano RS, Dubroja N, Shankar G, Bosisio FM, Roussel E, Verbiest A, Finotello F, Ausserhofer M, Lambrechts D, Boeckx B, Wozniak A, Boon L, Kerkhofs J, Zucman-Rossi J, Albersen M, Baldewijns M, Beuselinck B, Garg AD. Kinget L, et al. Among authors: albersen m. Nat Med. 2024 Aug;30(8):2375-2376. doi: 10.1038/s41591-024-03174-5. Nat Med. 2024. PMID: 39009782 No abstract available.
294 results